# TNG456

Source: https://onco.cc/drugs/tng456/  
OnCo record `tng456` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TNG456 is an experimental small-molecule drug from Tango Therapeutics in phase 2 trials for non-small-cell lung cancer and glioma & glioblastoma, aimed at PRMT5 (MTAP-deleted cancers).

## Summary

TNG456 is a small-molecule drug developed by Tango Therapeutics. Its target is PRMT5 (MTAP-deleted cancers) (the sponsor names PRMT5). The sponsor states: A selective PRMT5 inhibitor being developed for cancers with MTAP loss/deletion, including glioblastoma. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer and glioma & glioblastoma. The largest, NCT06810544, plans to enrol 191 participants with primary completion expected 2027-03-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: small molecule
- Mechanism: A selective PRMT5 inhibitor being developed for cancers with MTAP loss/deletion, including glioblastoma.

## Sources

- ClinicalTrials.gov: trials of TNG456: https://clinicaltrials.gov/search?intr=TNG456
- Sponsor pipeline page: https://tangotx.com/pipeline/

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [PRMT5 (MTAP-deleted cancers)](https://onco.cc/targets/prmt5-mtap/)
- companies: [Tango Therapeutics](https://onco.cc/companies/tango-therapeutics/)
- trials: [Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss](https://onco.cc/trials/nct06810544/)

---
JSON: https://onco.cc/api/v1/entities/tng456.json